A Safety and Pharmacodynamics Study of Temelimab, an anti‐HERV‐W‐Env Monoclonal Antibody, in Type 1 Diabetes Patients

Authors

Keywords

Journal

Volume -, Issue -, Pages -

Publisher

Wiley

Online

2020-02-20

DOI

10.1111/dom.14010

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now